Prof. MUDr. Ondřej Viklický, CSc.
Klinika nefrologie TC IKEM, Praha
Prof. MUDr. Ondřej Viklický, CSc., narozený 23. února 1966 v Praze, je profesorem vnitřního lékařství, přednostou Kliniky nefrologie TC IKEM v Praze a vedoucím lékařem Transplantační laboratoře CEM IKEM.
V letech 1985 – 1991 studoval všeobecné lékařství na 1. Lékařské fakultě Univerzity Karlovy v Praze, kde byl v roce 2005 jmenován docentem pro obor vnitřního lékařství. V roce 2009 byl jmenován profesorem pro obor vnitřních nemocí.
V letech 1997-1998 pracoval v transplantační laboratoři v Essenu. Věnuje se pregraduálnímu a postgraduálnímu vzdělávání studentů a lékařů, je školitelem Ph.D. studentů a řešitelem grantů MZ ČR, Grantové agentury ČR, Agentury pro zdravotnický výzkum ČR a EU s transplantační tématikou. Aktivně se účastní domácích i zahraničních kongresů.
Doposud publikoval mimo jiné 150 článků indexovaných v PubMed. Je hlavním autorem monografií Transplantace ledviny v klinické praxi, Doporučené postupy a algoritmy v nefrologii, Predialýza a Klinická nefrologie, 2., zcela přepracované a doplněné vydání.
Je předsedou Společnosti pro orgánové transplantace SOT ČLS JEP, členem výboru České nefrologické společnosti a členem výboru Spolku lékařů českých v Praze. V letech 2012-2014 byl předsedou České nefrologické společnosti a členem výboru České transplantační společnosti. Je zakládajícím členem pracovní skupiny ERA-EDTA pro transplantace DESCARTES a členem Transplantation Scientific Committee.
Prof. MUDr. Ondřej Viklický, CSc. je autorem těchto článků v časopise Postgraduální nefrologie:
Porrett PM, Orandi BJ, Kumar V, et al. First clinical‑grade porcine kidney xenotransplant using a human decedent model. Am J Transplant 2022 Jan 20. doi: 10.1111/ajt.16930. Epub ahead of print.
Loupy A, Aubert O, Reese PP, et al. Organ Procurement and Transplantation During the COVID‑19 Pandemic. Lancet 2020;395:e95–e96.
Issa N, Lopez CL, Denic A, et al. Kidney Structural Features from Living Donors Predict Graft Failure in the Recipient. J Am Soc Nephrol 2020;31:415–423.
Fu R, Kim SJ, de Oliveira C, Coyte PC. An instrumental variable approach confirms that the duration of pretransplant dialysis has a negative impact on the survival of kidney transplant recipients and quantifies the risk. Kidney Int 2019;96:450–459.
Pascual J, Berger SP, Witzke O, et al.
Eskandary F, Regele H, Baumann L, et al.
A Randomized Trial of Bortezomib in Late Antibody‑Mediated Kidney Transplant Rejection.
J Am Soc Nephrol 2018;29:591–605.
Wiebe C, Rush DN, Nevins TE, et al.
Jordan SC, Lorant T, Choi J, et al.
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med 2017;377:442–453.
Peters‑Sengers H, Berger SP, Heemskerk MB, et al.
Stretching the Limits of Renal Transplantation in Elderly Recipients of Grafts from Elderly Deceased Donors. J Am Soc Nephrol 2017;28:621–631.
Origüen J, et al.
Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. Am J Transplant 2016;16:2943–2953.
Orandi BJ, Luo X, Massie AB, et al. Survival Benefit with Kidney Transplants from HLA‑Incompatible Live Donors. N Engl J Med 2016;374:940–950.
Grams ME, Sang Y, Levey AS, et al. Kidney‑failure risk projection for the living kidney‑donor candidate. N Engl J Med 2015 Nov 6. [Epub ahead of print].
Niemann CU, et al. Therapeutic hypothermia in deceased organ donors and kidney‑graft function. N Engl J Med 2015;373:405–414.
Debout A, Foucher Y, Trébern‑Launay K, et al. Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney Int 2015;87:343–349.
Gandolfini I, Buzio C, Zanelli P, et al. The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pretransplant donor biopsy assessment: Distribution and association with graft outcomes. Am J Transplant 2014;14:2515–2525.
Carpenter MA, John A, Weir MR, et al. Cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial. J Am Soc Nephrol 2014, doi: 10.1681/ASN.2013040435
Ducloux D, et al. Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients. J Am Soc Nephrol 2014;25. doi: 10.1681/ASN.2013060663, in press.
Loupy A, Lefaucheur C, Vernerey D, et al. Complement‑binding anti‑HLA antibodies and kidney‑allograft survival. N Engl J Med 2013;369:1215–1226.
Ohashi Y, Thomas G, Nurko S, Stephany B, Fatica R, Chiesa A, Rule AD, Srinivas T, Schold JD, Navaneethan SD, Poggio ED. Association of metabolic syndrome with kidney function and histology in living kidney donors. Am J Transplant 2013;13:2342–2351.
Lenihan CR, Montez‑Rath ME, Scandling JD, Turakhia MP, Winkelmayer WC. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transpl 2013;13:1566–1575.
Melcher ML, Leeser DB, Gritsch HA, Milner J, Kapur S, Busque S, Roberts JP, Katznelson S, Bry W, Yang H, Lu A, Mulgaonkar S, Danovitch GM, Hil G, Veale JL. Chain transplantation: initial experience of a large multicenter program. Am J Transplant. 2012;12:2429–2436.
Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil‑Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J; TUMORAPA Study Group. Sirolimus and secondary skin‑cancer prevention in kidney transplantation. N Engl J Med 2012;367:329–339.
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O; on behalf of the ZEUS study investigators. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‑year results from the randomized ZEUS study. Am J Transplant 2012;12:1528–1540.
Choukroun G, Kamar N, Dussol B, et al., for the CAPRIT study Investigators. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012;23:360–368.
Hurst FP, Belur P, Nee R, Agodoa LY, Patel P, Abbott KC, Jindal RM. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States renal data system. Transplantation. 2011;92:36–40.
Geetha D, Eirin A, True K, et al. Renal transplantation in antineutrophil cytoplasmic antibody‑associated vasculitis: A multicenter experience. Transplantation 2011;91:1370–1375.
De Mauri A, Brambilla M, Chiarinotti D, Matheoud R, Carriero A, De Leo M. Estimated radiation exposure from medical imaging in hemodialysis patients. J Am Soc Nephrol 2011;22:571–578.
Stegall MD, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S, Dean PG, Prieto M, Amer H, Textor S, Schwab T, Cosio FG. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011;11:698–670.
Navarro MD, Lopez‑Andreu M, Rodriguez‑Benot A, et al. Significance of preimplantation analysis of kidney biopsies from expanded criteria donors in long‑term outcome. Transplantation 2011;91:432–439.
Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004–2014.
Udayaraj UP, Casula A, Ansell D, Dudley CRK, Ravanan R. Chronic kidney disease in kidney transplant recipients – it is different from chronic native kidney disease? Transplantation 2010;90:765–770.
Contreras G, Mattiazzi A, Guerra G, Ortega LM, Tozman EC, Li H, Tamariz L, Carvalho C, Kupin W, Ladino M, LeClercq B, Jaraba I, Carvalho D, Carles E, Roth D. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010;21:1200–1207.
Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner W-D, Banas B, Jauch K-W; for the SMART-Study Group. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010;90:175–183.
Gallagher MP, Kelly PJ, Jardine M, Pekovic V, Cass A, Craig JC, Eris J, Webster AC. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852–858.
Ayus JC, Achinger SG, Lee S, Sayegh MH, Go AS. Transplant nephrectomy associates with improved survival in patients with failed renal allograft. J Am Soc Nephrol 2010;21:374–380.
Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor‑based primary therapy for antibody‑mediated renal allograft rejection. Transplantation 2010;89:277–284.
Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six‑month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009;20:2449–2458.
Trappe R, Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Anagnostopoulos I, Doerken B, Riess H. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009;9:2331–2337.
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C. Comparison of combination plasmapheresis/IVIg/Anti-CD20 versus high-dose IVIg in the treatment of antibodymediated rejection. Am J Transplant 2009;9:1099–1107.
Quintana LF, Gonzales AS, Kalko SG, Bañon-Maneus E, Sole M, Diekman F, Gutierrez-Dalma A, Abian J, Campistol JM. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009;20:428–435.
Moers C, Smits JM, Maathuis MHJ, et al. Machine perfusion or cold storage in deceased – donor kidney transplantation. N Engl J Med 2009;360:7–19.
Zarkhin V, Li L, Kambham N, Sigdel T, Salvatiera O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008;8:2607–2617.
Eng HS, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex® predict late graft loss. Am J Transplant 2008;8:2335–2342.
van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008;8:1711–1718.
Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long‑term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008;8:975–983.
Kim HW, Seok HJ, Kim TH, Han DJ, Yang WS, Park SK. The experience of pregnancy after renal transplantation: pregnancies even within postoperative 1 year may be tolerable. Transplantation 2008;85:1412–1419.
Silva Jr HT, Yang HC, Abouljound M, et al. One‑year results with extended‑release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007;7:595–608.
Ekberg H, Tedesco‑Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, for the ELITE–Symphony Study. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. N Eng J Med 2007;357:2562–2575.
Frei U, Noeldeke J, Machold-Fabrizii V, Arbogast H, Margreiter R, Fricke L, Voiculescu A, Kliem V, Ebel H, Albert U, Lopau K, Schnuelle P, Nonnast-Dani-el B, Pietruck F, Offermann R, Persijn G, Bernasconi C. Prospective age-matching in elderly kidney transplant recipients – a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant. 2007, Oct 31, in-press.
Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, Knoll G, Lachance JG, Landsberg D, Shapiro J, Shoker A, Yilmaz S. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007;7:2538-2545.
Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, de Ligny BH, Rostaining L, Thervet E, Szelag JC, Rerolle JP, Rousseaz A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal trans-plantation. Am J Transplant 2007;7:2496–2503.
Ansell D, Udayaraj UP, Steenkamp R, Dudlej CRK. Chronic renal failure in kidney transplant recipients. Do they receive optimum care? Data from the UK renal registry. Am J Transplant 2007;7:1167–1176.
Vincenti F, Friman S, Schuermann E, Rostaing L, Nenesen T, Campistol JM, et al., on behalf of the DIRECT (Diabetes Incidence after Renal Transplantation: Neoral® C2 Monitoring Versus Tacrolimus) Investigators. Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. Am J Transplant 2007;7:1506–1514.
Pelle G, Vikomt S, Levy PP, Hertig A, Ouali N, Chassis C, Arlet G, Rondelu E, Vandewalle A. Acute pyelonephritis represents a risk factor impairing long‑term kidney graft function. Am J Transplant 2007;7:899–907.
Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff ´05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy („CAN“). Am J Transplant 2007;7:518–526.
Tostivint I, du Montcel ST, Jaudon MC, Mallet A, Le Hoang P, Bodaghi B, Deray G, Bagnis CI. Renal outcome after ciclosporin‑induced nephrotoxicity. Nephrol Dial Transplant 2007;22:880–885.
Nankivell BJ, Wavamunno MD, Borrows RJ, Vitalone M, Fung CL‑S, Allen RDM, Chapman JR, O’Connell PJ. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transpl 2007;7:366–376.
Hamer RA, Chow CL, Ong ACM, McKane WS. Polycystic kidney disease is a risk factor for new‑onset diabetes after transplantation. Transplantation 2007;83:36–40.
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D for the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab for induction in renal transplantation. N Engl J Med 2006;355:1967–77.
Ibernon M, Goma M, Moreso F, Falladova X, Hueso M, Cruzado JM, Torras J, Bestard O, Grinyo JM, Seron D. Subclinical rejection impairs glomerular adaptation after renal transplantation. Kidney Int 2006;70:557–561.
Nissel R, Latta K, Gagnadoux MF, Kelly D, Hulton S, Kemper MJ, Ruder H, Soderdahl G, Otte JB, Cochat P, Roquet O, Jamieson NV, Haffner D. Body growth after combined liver-kidney transplantation in children with primary hyperoxaluria type 1. Transplantation 2006;82:48–54.
Sun Q, Liu ZH, Ji S, et al. Late and early C4d-positive acute rejection: Different clinico-histopathological subentities in renal transplantation. Kidney Int 2006;70:377–383.
Gallon L, Perico N, Dimitrov BD, et al. : Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006;6:1617–1623.
Buchanan C, Smith L, Cobett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006;6:770–774.
Maes B, Hadaya K, de Moor B, et al. Severe diarrhoea in renal transplant patiens:results of the DIDACT study. Am J Transplant 2006;6:1466–1472.
Gore JL, Pham PT, Danovitch GM, Wilkinson AH, Rosenthal JT, Lipshutz GS, Singer JS. Obesity and outcome following renal transplantation. Am J Transplant 2006;6:357–363.
Stegall MD, Gloor J, Winter JL, Moore SB, DeGoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346–351.
Daniel C, Tendere L, Ammann K, Schulze-Lohoff E, Hauser IA, Hugo C. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005;5:2849–1861.
Gogh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M, McCarthy ET, Savin VJ.. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005;5:2907–2912.
Takase O, Marumo T, Omak N, Hirahashi J, Takayanagi A, Hishikawa K, Hayashi M, Shimizu N, Fujita T, Saruta T. NF- kB -dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int 2005;68:464-473.
Lemahieu WPD, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: No interaction with tacrolimus. Am J Transplant 2005;5:2236-2243.
Swarz A, Gwinner W, Hiss M, Raermacher J, Mengel M, Haller H. : Safety and adequacy of renal transplant protocol biopsy. Am J Transplant 2005;5:1992-1996.
Kuypers DR, Vandooren AK, lerut E, Evenepoel P, Clara K, Snoeck R, Naesens L, Vanrenterghem Y. : Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005;5:1997-2004.
Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005;45:1051-1060.
Li C, Sun BK, Lim SW, et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 2005;79:1522-1529.
Fujihara CK, Velho M, Malheiros DMAC, Zatz R. An extreme high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005;67:1913–1924.
Verhave JC, Hillege HL, Burgerhor JGM, Gansevoort RT, De Zeeuw D, De Jong PE, for the PREVEND study group. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005;67:1967–1973.
Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythro poietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005;79:367-368.
Schwarz A, Mengel M, Gwinner W, Radermacher J, Hiss M, Kreipe H, Haller H. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005;67:341–348.
Wyatt CM, Arons RR. The burden of acute renal failure in nonrenal solid organ transplantation. Transplantation 2004;78,1351ń1355.
Benigni A, Corna D, Zoja C, Longaretti L, Gagliardini E, Perico N, Hoffman TM, Remuzzi G. Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. J Am Soc Nephrol 2004;15:2666-2674.
Patel NSA, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction cause by ischemia/reperfusion in the mouse kindey in vivo. Kidney Int 2004;66:983-989.
Ninova D, Covarrubias M, Rea DJ, Park WD, Grande JP, Stegall MD. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor- β1 and α-smooth muscle actin. Transplantation 2004;78 3):338-344.
Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A. Pharmacoepidemiology of anemia in kidney transpant recipients. J Am Soc Nephrol 2004;15:1347-1352.
Schaub M, Ploetz CJ, Gerbaulet D, Fang L, Kranich P, Stalbauer THW, Goettman U, Yard BA, Braun C, Schnuelle P, van der Woude FJ. Effect of dopamine on inflammatory status in kidneys of brain-dead rats. Transplantation 2004;77:333-1340.
Pratschke J, Paz D, Wilhelm MJ, Laskowski I, Kofla G, Vergopoulos A, MacKEnzie HJ, Tullius SG, Neuhaus P, Hancock WW, Volk HD, Tilney NL. Donor hypertension increases graft immunogenicity and intensifies chronic changes in long-surviving renal allografts. Transplantation 2004;77:43-48.
Fan Zhang, Yaw L. Siow, Karmin O. Hyperhomocysteinemia activates NF- κβ and inducible nitric oxide synthese in the kidney. Kidney Int 2004;65:1327-1338.
Morris PJ, Monaco AP. Tolerance comes of age. Editorial comment.
Transplantation 2003;76:1407-1409.
Billingham RE, Brent L, Medawar PBFRS. "Actively acquired tolerance" of foreign cells.
Transplantation 2003;76:1409-412.
Hasek M. Vegetative hybridization of animals by joint blood
circulation during embryonal development. Transplantation
2003;76:1412-1421.
Fabre JW. The 50th anniversity of tolerance.
Transplantation 2003;76: 1421-1423.
Brent L. Commentary on the "birth" of immunologic tolerance
half a century ago. Transplantation 2003;76:1423-1424.
McLaren A. International rapprochement, 50 years ago.
Transplantation 2003;76:1425.
Ivanyi J. Comments from the translator of Hasekís
article. Transplantation 2003;76:1425.